Abstracts Archive - Page 121 of 2425 - ACR Meeting Abstracts

Abstract Number: 1632 • ACR Convergence 2024
Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?
Augustine Jose¹, Molly Thabah², Chengappa Kavadichanda³, Jagan K L², Christina Mariaselvam⁴ and Vir Singh Negi⁵, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴JIPMER, Puducherry, Puducherry, India, ⁵AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Ultrasonography can measure vascular intimal-medial thickness (IMT) and delineate the degrees of stenosis in Takayasu arteritis (TAK). Further, higher IMT has been reported in…
Abstract Number: 1546 • ACR Convergence 2024
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Anisha M. Patel¹, Carmen Ng¹, Lisa Lindsay¹, Zhiyu Xia², William F. Pendergraft III³ and Maria Dall'Era⁴, ¹Genentech, Inc., South San Francisco, ²Genentech, Inc., Sou, ³Genentech, Inc., Chapel Hill, NC, ⁴UCSF, Corte Madera, CA
Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
Abstract Number: 1619 • ACR Convergence 2024
Challenges in Managing Polymyalgia Rheumatica and Giant Cell Arteritis: Steroid Dependence and Preventive Care
Vivekanand Tiwari¹, chih fang², Katherine loomba², Nisha Khubchandani², shikha shah² and William Rigby³, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Hitchcock Medical Center, Lebanon, ³Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
Abstract Number: 1634 • ACR Convergence 2024
A Lexicon of Signs and Symptoms of Giant Cell Arteritis: An International Expert Consensus
Medha Soowamber¹, Milena Bond², Carol Langford³, Zahi Touma¹, Catalina Sanchez Alvarez⁴, Andy Abril⁵, Sibel Aydin⁶, FRANK HARTMUT DR. BUTTGEREIT⁷, Dario Camellino⁸, Maria Cid⁹, Peter Grayson¹⁰, Bernhard Hellmich¹¹, William Lichliter¹², Tanaz Kermani¹³, Nader Khalidi¹⁴, Sarah Mackie¹⁵, Eric Matteson¹⁶, Mehrdad Maz¹⁷, Peter Merkel¹⁸, Paul Monach¹⁹, Lorna Neill²⁰, Cristina Ponte²¹, Carlo Salvarani²², Wolfgang Schmidt²³, Peter Villiger²⁴, Kenneth Warrington²⁵, Madeline Whitlock²⁶, Sofia Ramiro²⁷ and Christian Dejaco²⁸, ¹University of Toronto, Toronto, ON, Canada, ²Unit of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsus Medical University, Bruneck, Italy, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Florida, Gainesville, FL, ⁵Mayo Clinic, Ponte Vedra Beach, FL, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸La Colletta hospital, Arenzano, Italy, ⁹Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹¹Medius Kliniken, Kirchheim unter Teck, Germany, ¹²patient, Vienna, Austria, ¹³University of California Los Angeles, Santa Monica, CA, ¹⁴McMaster University, Hamilton, ON, Canada, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷The University of Kansas Medical Center, Kansas City, KS, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹VA Boston Healthcare System, Boston, MA, ²⁰Patient Charity Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Nethy Bridge, United Kingdom, ²¹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal, ²²Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ²³Immanuel Krankenhaus Berlin, Berlin, Germany, ²⁴Medical Center Monbijou, Bern, Switzerland, ²⁵Mayo Clinic, Rochester, MN, ²⁶Southend University Hospital, Southend, United Kingdom, ²⁷Leiden University Medical Center, Bunde, Netherlands, ²⁸Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: The lack of standardized definitions and descriptors for clinical manifestations of giant cell arteritis (GCA) leads to variable interpretations of findings in clinical practice…
Abstract Number: 1568 • ACR Convergence 2024
Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study
Arifa Javed¹, Lilit Grigoryan², Alex Luta³, Sumbal Wajid², Lee Shapiro⁴, Virginia Steen⁵ and Swati Mehta⁶, ¹Albany Medical Center, Rensselaer, NY, ²Albany Medical Center, Albany, NY, ³MedStar Georgetown University Hospital, Rockville, MD, ⁴Albany Medical College, Stillwater, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but life-threatening complication of systemic sclerosis (SSc), characterized by malignant hypertension and acute kidney injury (AKI). Proteinuria when present at the time of…
Abstract Number: 1603 • ACR Convergence 2024
Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial
Frank B. Cortazar¹, Duvuru Geetha², Salem Almaani³, Christina Song⁴, Tomasz M. Wilmanski⁴, Alana M. Bozeman⁴, Peter Merkel⁵ and David Jayne⁶, and ADVOCATE Study Group, ¹New York Nephrology Vasculitis and Glomerular Center, Saint Peter’s Hospital-Albany, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³The Ohio State University Medical Center, Columbus, OH, ⁴Amgen Inc., Thousand Oaks, CA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: The utility of measuring serial antineutrophil cytoplasmic autoantibody (ANCA) levels to guide treatment in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) is controversial.…
Abstract Number: 1633 • ACR Convergence 2024
Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients
Koichi Sugihara¹, Risa Wakiya², Hiromi Shimada², Taichi Miyagi², Yusuke Ushio², Rina Mino², Mao Mizusaki³, Hayamasa yamaguchi³, Naoto Manabe³, Shusaku Nakashima² and Hiroaki dobashi², ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, ²Kagawa University, Miki-cho, Kita-gun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Arthritis associated with Behcet's disease (BD) has been reported to be related to patients' quality of life and associated with skin and mucosal lesions.…
Abstract Number: 1621 • ACR Convergence 2024
Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study
Ufuoma Mamoh¹, Soziema Salia¹, Joan Morny², Jesse Odion³, Elem Ewuru⁴, Precious Onobraigho⁵, Eugene Omoike⁵, Oyidia Ijioma⁶, Osaruese Ezomo⁷ and Ehizogie Edigin⁸, ¹Medstar Union Memorial Hospital, Baltimore, MD, ²Piedmont Athens Regional Medical Center, Athens, GA, ³Royal Devon University Healthcare NHS Foundation Trust, Barnstaple, United Kingdom, ⁴Acute and Emergency Care United Kingdom Medway Maritime Hospital, Gillingham, ⁵College of Medicine, University of Benin, Benin, Nigeria, ⁶Department of Clinical Psychiatry, University of South Wales, Wales, United Kingdom, ⁷Department of Gastroenterology, Spire Manchester Hospital, Manchester, United Kingdom, ⁸The University of Texas Health Science Center, houston, TX
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis, typically affecting young children, and is the leading cause of acquired heart disease in children in developed…
Abstract Number: 1609 • ACR Convergence 2024
Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital
Cristina Valero¹, Claudia Valenzuela², Elisa Martínez-Besteiro³, Patricia Quiroga Colina⁴, Arantzazu Alfranca⁵, Esther Vicente-rabaneda⁶, Santos Castañeda⁶ and Rosario García-Vicuña⁷, ¹Hospital de la Princesa, Madrid, Spain, ²ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, ³Pulmonology Service, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Immunology Service, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Madrid, Spain
Background/Purpose: The prevalence of ANCA positivity at diagnosis of interstitial lung disease (ILD) ranges between 4-36% for anti-MPO and 2-4% for anti-PR3. ILD is more…
Abstract Number: 1607 • ACR Convergence 2024
Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Sebastian Klapa¹, Sabrina Arnold², Antje Müller², Andreas Koch³, Anja Staehle⁴, Wataru Kähler³, Harry Heidecke⁵, Gabriela Riemekasten² and Peter Lamprecht², ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, ⁴University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany
Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
Abstract Number: 1520 • ACR Convergence 2024
The Influence of Trauma on Features of Type 2 SLE
Jennifer Rogers¹, Megan Clowse², David Pisetsky³, Jayanth Doss⁴, Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Rebecca Sadun⁴, Kai Sun⁴ and Amanda Eudy⁶, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University, Raleigh, NC
Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown. Since trauma has…
Abstract Number: 1523 • ACR Convergence 2024
Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020
Husam El Sharu, East Carolina University, Greenville, NC
Background/Purpose: Introduction: In the past decade, the incidence of Lupus Nephritis (LN) flares linked to mortality has generally decreased, though an upward trend has emerged…
Abstract Number: 1555 • ACR Convergence 2024
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Vibeke Strand¹, Kenneth Kalunian², Ian Bruce³, Caroline Seo⁴, Kai Wai Lee⁵, Jacob Knagenhjelm⁶ and Catharina Lindholm⁶, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2 We previously demonstrated that, compared with placebo, a…
Abstract Number: 1627 • ACR Convergence 2024
Real-World Data on Imaging Tests, Specifically Temporal Artery Ultrasound, in Giant Cell Arteritis in Japan: A Multicenter Retrospective Study
Nobuhiro Oda¹, Sho Fukui², Toshihiro Yamaguchi³, Fumika Nagase⁴, Takanori Ito⁵, Mitsuru Watanabe⁵, Yoichiro Haji⁴, Yasuhiro Suyama⁶, Atsushi Nomura⁷, Eishi Uechi⁸, Masei Suda³, Naoho Takizawa⁴, Ryo Rokutanda⁹ and Hiromichi Tamaki¹⁰, ¹Kameda medical center, Department of Rheumatology, Higashi-cho, Kamogawa, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³Suwa Central Hospital, Department of Rheumatology, Nagano, Japan, ⁴Chubu Rosai Hospital, Department of Rheumatology, Aichi, Japan, ⁵Daido Hospital, Department of Rheumatology, Aichi, Japan, ⁶NTT Medical Center Tokyo, Department of Rheumatology, Tokyo, Japan, ⁷Ushiku Aiwa General Hospital, Department of Rheumatology, Ibaraki, Japan, ⁸Yuai Medical Center, Department of Rheumatology, Okinawa, Japan, ⁹Kameda medical center, Department of Rheumatology, Chiba, Japan, ¹⁰St. Luke’s International Hospital, Immuno-Rheumatology Center, Tokyo, Japan
Background/Purpose: In the 2022 ACR classification criteria for giant cell arteritis (GCA), temporal artery ultrasound (TAU) is granted the same diagnostic value as temporal artery…
Abstract Number: 1615 • ACR Convergence 2024
Is Regular Vascular Imaging Scheduled Essential in the Follow-Up of Takayasu Arteritis? A Large-Scale Multicenter Cohort Study
Fatih Yildirim¹, Cemal Bes², Muhammet Emin Kutu³, Fatih Tastekin⁴, Gokhan Keser⁵, Tugba Ocak⁶, Ediz Dalkilic⁶, Yavuz Pehlivan⁶, Hasan Kocaayan⁷, Servet Akar⁷, Sema İsik⁸, Ahmet Omma⁹, Senar San¹⁰, Ayten Yazici¹¹, Ayse Cefle¹¹, Safiye Bakkal¹², Gökçe Kenar¹³, Fatos Onen¹², Aysegül Avcu¹⁴, Fatma Alibaz Öner¹⁵, Haner Direskeneli¹⁵, Burcu Ceren Uludogan¹⁶, Nazife Sule yaşar Bile¹⁶ and Nilüfer Alpay Kanıtez¹⁷, ¹University of Health Sciences Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey, İstanbul, Turkey, ²University of Health Sciences Başakşehir Çam and Sakura City HospitalUniversity of Health Sciences Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey, İstanbul, Turkey, ³Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁴Ege University School of Medicine, Rheumatology, İzmir, Turkey, İzmir, Turkey, ⁵Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ⁶Uludağ University Faculty of Medicine, Rheumatology, Bursa, Turkey, Bursa, Turkey, ⁷İzmir Katip Celebi University School of Medicine, Rheumatology, İzmir, Turkey, İzmir, Turkey, ⁸University of Health Sciences Ankara Bilkent City Hospital, Rheumatology, Ankara, Turkey, Ankara, Turkey, ⁹Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁰Kocaeli University Faculty of Medicine, Rheumatology, Kocaeli, Turkey, Kocaeli, Turkey, ¹¹Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹²Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, İzmir, Turkey, ¹³Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, İstanbul, Turkey, ¹⁵Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁶Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹⁷Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: The understanding of progression or minimal disease activity in patients with Takayasu arteritis (TA) can be complicated due to the possibility of mild vascular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].